Navigation Links
Global Rabies Treatment May be Possible with NanoViricides Drugs

WEST HAVEN, Conn.--(BUSINESS WIRE)--May 14, 2007 - NanoViricides, Inc. (Pink Sheets: NNVC) discussed today the results of recent animal studies against rabies that were presented along with the successful BSL3 in vitro studies against a Clade 2 H5N1 virus at the 23rd Annual Symposium of the Pan American Society for Clinical Virology in Tampa, FL, on Wednesday, May 2. (Pan American Society for Clinical Virology (PASCV): Clinical Virology Symposium)

The animal studies against rabies were conducted in Vietnam using the Challenge Standard Virus strain at a highly lethal infection level of 1,000 LD50 given directly into the brain. NanoViricides drugs based on the broad-spectrum chemicals ligand class, rabies-specific receptor peptide ligand class, as well as rabies-antibody-derived ligand class were tested in both direct intracerebral treatment as well as intraperitoneal treatment modalities. Human anti-Rabies Immunoglobulin (RIG), a commercial standard rabies treatment, was used as positive control.

A 30% survival rate with two of the nanoviricides and 20% survival rate with another two nanoviricides was found in mice treated intracerebrally, Additionally, a 20% survival rate was found with two of these four nanoviricides even on intraperitoneal treatment. All mice treated with RIG died. All of the nanoviricide drug candidates showed efficacy superior to the RIG standard, as measured by various end-points including survival and body-weight.

RIG together with rabies vaccine are given as post-exposure prophylaxis (PEP) in developed countries. However, once clinical signs are evident (prodrome phase), rabies is 100% fatal in humans. Rabies is a very important disease in developing nations. More than 50 cases of rabies infection occur in the US annually. RIG is too expensive to be used in most patients in developing nations. The Company believes that the chemical ligand-based nanoviricides can be made ine
'"/>




Page: 1 2

Related medicine technology :

1. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
2. New Report Looking at Chiral Technologies Analyzes the Global Market Growth Forecasts Driven By Two Very Important Components as Single Isomer Drugs and Single Enantiomer Pharmaceuticals
3. New Study Reveals Limitations of a Complex and Challenging Global Tuberculosis Drug Marketplace
4. Point of Care Strep Tests Speed Treatment, Lower Costs
5. Rapid HIV Testing Increases Possibility of Treatment
6. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
7. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
10. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
11. TMC125 Showed Significant Virologic Response at Week 24 in Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3 Trials
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Global Rabies Treatment May Possible with NanoViricides Drugs
(Date:11/22/2014)... , Nov. 21, 2014  Particle Sciences, ... devices, has developed and manufactured a new innovative ... the Research and Development arm of Exeltis Pharmaceuticals.  ... of Project Management at Particle Sciences, "This vaginal ... utilizing our material sciences and modeling expertise.  We ...
(Date:11/22/2014)... Nov. 21, 2014 Many power shifts ... growing influence of patients in the biopharmaceutical market ... Now, more than ever, understanding how to effectively ... products is essential. According to ... benchmarked companies spent about two-thirds of their patient-focused ...
(Date:11/21/2014)... Nov. 21, 2014  The University of Maryland,s A. ... ceremonial groundbreaking of the new A. James Clark Hall ... building will cultivate transformative new engineering and biomedical technologies ... place at 10:00 a.m. on November 21 at the ... Parking Lot, adjacent to the Jeong H. Kim Engineering ...
Breaking Medicine Technology:Particle Sciences' Clinical Trial Supplies Group Manufactures Innovative Vaginal Ring 2New Report Details Importance of Adopting a "Patient Journey" Framework in Marketing 2University of Maryland Breaks Ground for A. James Clark Hall 2University of Maryland Breaks Ground for A. James Clark Hall 3University of Maryland Breaks Ground for A. James Clark Hall 4
... Study evaluates the efficacy of new device for detecting polyps ... ... Fla., Oct. 7 At the American College of,Gastroenterology Annual ... MD presented results from a,multi-institutional clinical study that evaluated the ...
... by ... with Celiac Disease, Additional Data Indicates Potential in Treating Inflammatory ... Corporation,presented results from two clinical studies this week at the ... CLIN 1001-004, the first Phase IIa trial conducted in celiac ...
Cached Medicine Technology:National Study Presented at ACG 2008 Confirms New Device Functions Like 'Rear-View Mirror' to Provide Improved View of the Colon 2National Study Presented at ACG 2008 Confirms New Device Functions Like 'Rear-View Mirror' to Provide Improved View of the Colon 3National Study Presented at ACG 2008 Confirms New Device Functions Like 'Rear-View Mirror' to Provide Improved View of the Colon 4National Study Presented at ACG 2008 Confirms New Device Functions Like 'Rear-View Mirror' to Provide Improved View of the Colon 5Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting 2Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting 3Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting 4Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting 5Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting 6
(Date:11/23/2014)... The FDA is Watching: , What Twitter, ... Dec. 11, 2014 ? Any Time at Your Convenience ... promotional activities is no longer limited to magazine and ... websites, Twitter, journal articles, TV appearances, Facebook and more. ... for On-Demand access to Timothy Ayers and Michelle Axelrod’s ...
(Date:11/22/2014)... SC (PRWEB) November 23, 2014 Every ... to their communities. AlignLife experience rapid growth in the ... a very unique opportunity. AlignLife of Simpsonville ... AlignLife offices for their first annual Toy Drive. These ... charity they would support with this year's toy drive. ...
(Date:11/22/2014)... November 23, 2014 A classic black prom ... the most famous dress suppliers, has unveiled its new items ... dresses are now offered at a big discount, up to ... offer. , The new black prom dresses, made with ... to meet the needs of all customers, the company provides ...
(Date:11/22/2014)... PA (PRWEB) November 22, 2014 “Due to ... said an inventor, from Gurnee, Ill. “While using the ice ... be and I thought there needed to be a safer ... invented the SPIKE BLOCK. , The SPIKE BLOCK offers added ... so, it would help to reduce injuries and damage associated ...
(Date:11/22/2014)... York (PRWEB) November 22, 2014 A ... morcellators ( http://www.morcellatorlawsuit2015.com ) in minimally-invasive hysterectomies and ... signatures since the end of October, Bernstein Liebhard LLP ... the petition as of November 21st, 2014. That represents ... 86,042 supporters had signed on to the campaign.* , ...
Breaking Medicine News(10 mins):Health News:FDAnews Announces The FDA is Watching: What Twitter, Tradeshows and TV Have in Common, On-Demand Webinar, Dec. 11, 2014 2Health News:FDAnews Announces The FDA is Watching: What Twitter, Tradeshows and TV Have in Common, On-Demand Webinar, Dec. 11, 2014 3Health News:FDAnews Announces The FDA is Watching: What Twitter, Tradeshows and TV Have in Common, On-Demand Webinar, Dec. 11, 2014 4Health News:FDAnews Announces The FDA is Watching: What Twitter, Tradeshows and TV Have in Common, On-Demand Webinar, Dec. 11, 2014 5Health News:Greenville Area AlignLife Offices Join Together for a Local Toy Drive 2Health News:New Black Prom Dresses from BellasDress.com 2Health News:Power Morcellator Petition Gains More than 450 Signatures Since October, Bernstein Liebhard LLP Reports 2Health News:Power Morcellator Petition Gains More than 450 Signatures Since October, Bernstein Liebhard LLP Reports 3Health News:Power Morcellator Petition Gains More than 450 Signatures Since October, Bernstein Liebhard LLP Reports 4
... ST. LOUIS, May 12 Allied Healthcare Products, Inc. (Nasdaq: ... the third quarter ending March 31, 2009, declined from about ... period, to a loss of about $450,000, or a negative ... the third quarter declined about 11 percent, or $1.5 million, ...
... May 12 With today,s release of the ... showing that the nation,s two largest programs are ... urged politicians to work together on reforms of ... Reform efforts will need to recognize the underlying ...
... to Depletion According to Latest Projections WASHINGTON , ... trustees, reports issued earlier today highlight the imperative to ... and Medicare, according to the American Academy of ... programs has deteriorated further during the past year and ...
... (NYSE: BMR ) today announced it has commenced ... pursuant to an effective shelf registration statement filed with the ... net proceeds of the offering to repay a portion of ... credit and for other general corporate and working capital purposes. ...
... people have the same genetic disease, why would one person ... or not at all? For a group of genetic diseases ... and Joubert syndrome the answer lies in one gene ... also seems to increase the risk of progressive blindness in ...
... suggests , , TUESDAY, May 12 (HealthDay News) -- Children,s ... cardiac death (DCD), according to researchers, who asked 124 ... about their policies in 2007 and 2008. , The ... that 72 percent of them had DCD policies, while ...
Cached Medicine News:Health News:Allied Healthcare Posts Third Quarter Loss 2Health News:Allied Healthcare Posts Third Quarter Loss 3Health News:Allied Healthcare Posts Third Quarter Loss 4Health News:Allied Healthcare Posts Third Quarter Loss 5Health News:Concord Coalition Says New Trustees' Report Demonstrates the Importance of Health Care Cost Control 2Health News:Actuaries: Trustees' Reports Warn of Looming Financial Challenges Facing Retirement Programs 2Health News:Actuaries: Trustees' Reports Warn of Looming Financial Challenges Facing Retirement Programs 3Health News:BioMed Realty Trust Announces Public Offering of 14,000,000 Shares of Common Stock 2Health News:BioMed Realty Trust Announces Public Offering of 14,000,000 Shares of Common Stock 3Health News:In retinal disease, sight may depend on second sites 2Health News:In retinal disease, sight may depend on second sites 3Health News:Organ Donation Policies Vary Among Children's Hospitals 2
Aire-Cuf® tracheostomy tubes are ideal for short-term to medium-term ventilator support....
Designed by a neonatalogist to reduce the number of steps required to suction meconium from the infants trachea when seconds count. Meconium suction system optimizes patient and provider safety....
KIMBERLY-CLARK BALLARD Neonatal and Pediatric TRACH CARE Manifold features lavage/irrigation port and locking thumb port. Multiple French sizes and packaging configurations. Gamma sterilized....
... Per-fit™ tubes are a dual ... of the disposable inner cannula ... provided in the procedural tray. ... tubes are available separately. Per-fit™ ...
Medicine Products: